» Articles » PMID: 22472085

Minocycline Corrects Early, Pre-plaque Neuroinflammation and Inhibits BACE-1 in a Transgenic Model of Alzheimer's Disease-like Amyloid Pathology

Overview
Publisher Biomed Central
Date 2012 Apr 5
PMID 22472085
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A growing body of evidence indicates that inflammation is one of the earliest neuropathological events in Alzheimer's disease. Accordingly, we have recently shown the occurrence of an early, pro-inflammatory reaction in the hippocampus of young, three-month-old transgenic McGill-Thy1-APP mice in the absence of amyloid plaques but associated with intracellular accumulation of amyloid beta petide oligomers. The role of such a pro-inflammatory process in the progression of the pathology remained to be elucidated.

Methods And Results: To clarify this we administered minocycline, a tetracyclic derivative with anti-inflammatory and neuroprotective properties, to young, pre-plaque McGill-Thy1-APP mice for one month. The treatment ended at the age of three months, when the mice were still devoid of plaques. Minocycline treatment corrected the up-regulation of inducible nitric oxide synthase and cyclooxygenase-2 observed in young transgenic placebo mice. Furthermore, the down-regulation of inflammatory markers correlated with a reduction in amyloid precursor protein levels and amyloid precursor protein-related products. Beta-site amyloid precursor protein cleaving enzyme 1 activity and levels were found to be up-regulated in transgenic placebo mice, while minocycline treatment restored these levels to normality. The anti-inflammatory and beta-secretase 1 effects could be partly explained by the inhibition of the nuclear factor kappa B pathway.

Conclusions: Our study suggests that the pharmacological modulation of neuroinflammation might represent a promising approach for preventing or delaying the development of Alzheimer's disease neuropathology at its initial, pre-clinical stages. The results open new vistas to the interplay between inflammation and amyloid pathology.

Citing Articles

Neprilysin-Mediated Amyloid Beta Clearance and Its Therapeutic Implications in Neurodegenerative Disorders.

Saxena S, Ansari S, Maurya V, Kumar S, Sharma D, Malhotra H ACS Pharmacol Transl Sci. 2024; 7(12):3645-3657.

PMID: 39698259 PMC: 11651204. DOI: 10.1021/acsptsci.4c00400.


Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-beta Complexities and Pioneering Precision Medicine Approaches.

Patwekar M, Patwekar F, Khan S, Sharma R, Kumar D Curr Top Med Chem. 2024; 24(19):1665-1682.

PMID: 38644708 DOI: 10.2174/0115680266295495240415114919.


Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.

Garmendia J, De Sanctis C, Das V, Annadurai N, Hajduch M, De Sanctis J Curr Neuropharmacol. 2023; 22(6):1080-1109.

PMID: 37898823 PMC: 10964103. DOI: 10.2174/1570159X22666231017141636.


NF-κB Pathway and Its Inhibitors: A Promising Frontier in the Management of Alzheimer's Disease.

Sivamaruthi B, Raghani N, Chorawala M, Bhattacharya S, Prajapati B, Elossaily G Biomedicines. 2023; 11(9).

PMID: 37761028 PMC: 10526355. DOI: 10.3390/biomedicines11092587.


Advances in the study of the molecular biological mechanisms of radiation-induced brain injury.

Gan C, Li W, Xu J, Pang L, Tang L, Yu S Am J Cancer Res. 2023; 13(8):3275-3299.

PMID: 37693137 PMC: 10492106.


References
1.
Fan R, Xu F, Previti M, Davis J, Grande A, Robinson J . Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci. 2007; 27(12):3057-63. PMC: 6672462. DOI: 10.1523/JNEUROSCI.4371-06.2007. View

2.
Varvel N, Bhaskar K, Kounnas M, Wagner S, Yang Y, Lamb B . NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest. 2009; 119(12):3692-702. PMC: 2786797. DOI: 10.1172/JCI39716. View

3.
Fagan S, Edwards D, Borlongan C, Xu L, Arora A, Feuerstein G . Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol. 2004; 186(2):248-51. DOI: 10.1016/j.expneurol.2003.12.006. View

4.
Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

5.
Weggen S, ERIKSEN J, Das P, Sagi S, Wang R, Pietrzik C . A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001; 414(6860):212-6. DOI: 10.1038/35102591. View